Cover Image
市場調查報告書

PharmaSphere:新興生物科技企業的投資報告 - 非上市股票(PE)、創業基金(VC)基金的策略性趨勢

PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding

出版商 GlobalData 商品編碼 297501
出版日期 內容資訊 英文 183 Pages
訂單完成後即時交付
價格
Back to Top
PharmaSphere:新興生物科技企業的投資報告 - 非上市股票(PE)、創業基金(VC)基金的策略性趨勢 PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding
出版日期: 2014年03月12日 內容資訊: 英文 183 Pages
簡介

本報告提供帶給美國和全球新興生物科技企業未來重大影響的,形成非上市股票(PE)、創業基金(VC)部門的目前趨勢與要素調查分析,再加上主要企業簡介等,為您概述為以下內容。

給(對)

第1章 目錄

第2章 簡介

第3章 美國的非上市股票(PE)、創業基金(VC)的產業趨勢

  • 2008年以後
  • 量優於價值
  • 醫療制度改革、成本的壓力
  • PE的交易:各治療領域
  • PE的壟斷收購
  • VC的投資趨勢
  • VC的投資
  • 融資趨勢
  • 風險企業支援
  • 加利福尼亞、麻薩諸塞州、紐約首先在VC投資

第4章 股票上市

  • 醫療部門的股票上市
  • 支援風險企業的新公開(IPO)
  • 支援風險企業的新興生物科技企業的IPO
  • 流動性的地位,富有魅力新興生物科技企業
  • 企業簡介和IPO詳細內容

第5章 PE企業:企業分析

  • 部門概要
  • 概要與投資組合管理、交易實際成果、相關交易等
    • TPG Capital
    • The Blackstone Group
    • Kohlberg Kravis Roberts
    • Warburg Pincus
    • Goldman Sachs Principal Investment Area
    • Advent International Corporation
    • Apollo Global Management
    • Bain Capital
    • CVC Capital Partners
    • Oaktree Capital Management
    • Hellman & Friedman

第6章 VC企業:企業分析

  • 部門概要
  • 概要與投資組合管理、交易實際成果、相關交易等
    • New Enterprise Associates
    • OrbiMed Advisors
    • Canaan Partners
    • Versant Ventures
    • New Leaf Venture Partners
    • Third Rock Ventures
    • Domain Associates
    • Kleiner Perkins Caufield & Byers
    • Clarus Ventures
    • Flagship Ventures
    • 其他

第7章 策略性預測

  • 新興生物科技企業的持續成長需要的新融資模式
  • 亞太地區活躍的成長繼續
  • 中小基金大幅度的交易活動
  • IPO活動增加
  • VC企業的壓力增加

第8章 附錄

圖表

目錄
Product Code: GDHC005PSR

GlobalData's "PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding" report provides in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry, bearing in mind that these are expected to have significant impact on the future of emerging biotechnology companies in the US and globally. Furthermore, the report identifies regions of the world that are attracting more investments in healthcare and discusses the various factors responsible for this trend. In addition, the report provides detailed profiles of 12 leading private equity firms, 15 top venture capital firms, and 15 US-based emerging biotechnology companies that completed initial public offerings in 2013.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each observation, strategy, and trend discussed, with the aim of providing you with the tools needed for making informed business decisions in the rapidly changing global investment landscape.

Highlights

Key Questions Answered

  • What are the current trends impacting emerging biotechnology investment in the US and globally?
  • What regions are witnessing noteworthy investment in healthcare and what are the factors driving such occurrences?
  • What therapeutic areas are attracting the most investment by private equity and venture capital firms and why?
  • What has been the trend of equity offerings in the healthcare sector since 2004 and what factors were responsible?
  • What is the strategic outlook of emerging biotechnology investment?

About the Report

This report is an essential source of information and analysis on emerging biotech investment, with significant emphasis on the US. GlobalData provides an in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry. The report highlights the various therapeutic areas attracting noteworthy funding in terms of the volume and value of new and follow-on investments and discusses the factors responsible for this trend. Furthermore, it provides a strategic outlook on future trends that are expected in private equity and venture capital funding and how they will impact the growth and development of biotech companies globally.

Scope

  • Historical trend analysis of private equity and venture capital funding prior to- and after the financial market crash of 2008, including a change in the average value of completed deals in the healthcare industry
  • The report highlights how ongoing healthcare reform in parts of Europe and North America are resulting in a shift of deals activity involving private equity and venture capital firms to the Asia-Pacific
  • Discussion of therapeutic areas attracting significant investments, as well as the factors responsible for such trends
  • Detailed profiles of 12 leading private equity firms, 15 top venture capital firms, and 15 US-based emerging biotechnology companies that completed initial public offerings in 2013
  • Global strategic outlook on future trends that are expected in private equity and venture capital funding, as well as the need for a new financing model to drive the sustainable growth of emerging biotech companies.

Reasons to buy

  • Understand the current trends impacting emerging biotechnology investment in the US and globally
  • Evaluate the strategies being used by leading private equity and venture capital firms as they aim to minimize risk and ensure significant return on investment
  • Gain valuable insights into the investment strategies, deals, and portfolios of leading private equity and venture capital firms
  • Gain valuable insights into US-based, innovative emerging biotechnology companies with venture capital backing, their developmental pipelines, and strategic collaborations
  • Use this information as an independent source for your due diligence and transaction strategy

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
  • 2.2. Upcoming Related Reports
  • 2.3. Recently Published Reports

3. US Private Equity and Venture Capital Industry Dynamics

  • 3.1. Post-2008 Financial Market Crash: Volume of Capital Commitments to Private Equity Funds Show Signs of Recovery
    • 3.1.1. Venture Capital Fundraising Trend in the US
  • 3.2. Volume over Value: Decrease in the Average Value of Completed Private Equity Healthcare Deals between 2007 and 2013
  • 3.3. Healthcare Reform and Cost Pressures in Europe and North America Shifts Deal Activity to the Asia-Pacific Region
  • 3.4. Private Equity Deals by Therapy Area
    • 3.4.1. Central Nervous System, Immunology, Infectious Disease, Metabolic Disorders, and Oncology Enjoying Significant Investment
  • 3.5. Private Equity Buyouts of 2013
  • 3.6. Venture Capital Investment Trend
  • 3.7. Venture Capital Investment: Biotechnology Plays Second Fiddle to Software
  • 3.8. Seed-Stage Financing Shows Downward Trend
  • 3.9. Venture-Backed Exits in 2013
    • 3.9.1. Significant Venture-Backed Biotechnology Acquisitions in 2013
    • 3.9.2. Venture-Backed Mergers and Acquisition Witness Strong End to 2013
  • 3.10. California, Massachusetts, and New York Lead the Pack in Venture Capital Investment for 2013

4. Equity Offerings

  • 4.1. Equity Offerings in the Healthcare Sector
  • 4.2. Venture-Backed Initial Public Offerings in 2013
  • 4.3. Venture-Backed Emerging Biotech Initial Public Offerings in 2013
  • 4.4. Liquidity Position Makes Emerging Biotechs an Attractive Prospect for Investors
  • 4.5. Company Profiles and Initial Public Offer Details
    • 4.5.1. Intrexon Corporation (Stock Symbol: XON)
    • 4.5.2. Ophthotech Corporation (Stock Symbol: OPHT)
    • 4.5.3. PTC Therapeutics (Stock Symbol: PTCT)
    • 4.5.4. Portola Pharmaceuticals (Stock Symbol: PTLA)
    • 4.5.5. Agios Pharmaceuticals (Stock Symbol: AGIO)
    • 4.5.6. Chimerix (Stock Symbol: CMRX)
    • 4.5.7. Bluebird Bio (Stock Symbol: BLUE)
    • 4.5.8. Foundation Medicine (Stock Symbol: FMI)
    • 4.5.9. OncoMed Pharmaceuticals (Stock Symbol: OMED)
    • 4.5.10. Acceleron Pharma (Stock Symbol: XLRN)
    • 4.5.11. Prosensa Therapeutics (Stock Symbol: RNA)
    • 4.5.12. Epizyme (Stock Symbol: EPZM)
    • 4.5.13. Onconova Therapeutics (Stock Symbol: ONTX)
    • 4.5.14. Tetraphase Pharmaceuticals (Stock Symbol: TTPH)
    • 4.5.15. Esperion Therapeutics (Stock Symbol: ESPR)

5. Private Equity Firms: Company Drill-Downs

  • 5.1. Section Overview
  • 5.2. TPG Capital
    • 5.2.1. Overview and Portfolio Management
    • 5.2.2. Historical Deals Trend
    • 5.2.3. Healthcare-Related Deals in 2013
  • 5.3. The Carlyle Group
    • 5.3.1. Overview and Portfolio Management
    • 5.3.2. Historical Deals Trend
    • 5.3.3. Healthcare-Related Deals in 2013
  • 5.4. The Blackstone Group
    • 5.4.1. Overview and Portfolio Management
    • 5.4.2. Historical Deals Trend
    • 5.4.3. Healthcare-Related Deals in 2013
  • 5.5. Kohlberg Kravis Roberts
    • 5.5.1. Overview and Portfolio Management
    • 5.5.2. Historical Deals Trend
    • 5.5.3. Healthcare-Related Deals in 2013
  • 5.6. Warburg Pincus
    • 5.6.1. Overview and Portfolio Management
    • 5.6.2. Historical Deals Trend
    • 5.6.3. Healthcare-Related Deals in 2013
  • 5.7. Goldman Sachs Principal Investment Area
    • 5.7.1. Overview and Portfolio Management
    • 5.7.2. Historical Deals Trend
  • 5.8. Advent International Corporation
    • 5.8.1. Overview and Portfolio Management
    • 5.8.2. Historical Deals Trend
    • 5.8.3. Healthcare-Related Deals in 2013
  • 5.9. Apollo Global Management
    • 5.9.1. Overview and Portfolio Management
    • 5.9.2. Healthcare-Related Deals in 2013
  • 5.10. Bain Capital
    • 5.10.1. Overview and Portfolio Management
    • 5.10.2. Historical Deals Trend
    • 5.10.3. Healthcare-Related Deals in 2013
  • 5.11. CVC Capital Partners
    • 5.11.1. Overview and Portfolio Management
    • 5.11.2. Historical Deals Trend
  • 5.12. Oaktree Capital Management
    • 5.12.1. Overview and Portfolio Management
    • 5.12.2. Historical Deals Trend
  • 5.13. Hellman & Friedman
    • 5.13.1. Overview and Portfolio Management
    • 5.13.2. Historical Deals Trend

6. Venture Capital Firms: Company Drill-Downs

  • 6.1. Section Overview
  • 6.2. New Enterprise Associates
    • 6.2.1. Overview and Portfolio Management
    • 6.2.2. Historical Deals Trend
    • 6.2.3. Biotechnology Exits and Initial Public Offerings in 2013
  • 6.3. OrbiMed Advisors
    • 6.3.1. Overview and Portfolio Management
    • 6.3.2. Historical Deals Trend
    • 6.3.3. Biotechnology Exits and Initial Public Offerings in 2013
  • 6.4. Canaan Partners
    • 6.4.1. Overview and Portfolio Management
    • 6.4.2. Historical Deals Trend
    • 6.4.3. Biotechnology Exits and Initial Public Offerings in 2013
  • 6.5. Versant Ventures
    • 6.5.1. Overview and Portfolio Management
    • 6.5.2. Historical Deals Trend
    • 6.5.3. Biotechnology Exits and Initial Public Offerings in 2013
  • 6.6. New Leaf Venture Partners
    • 6.6.1. Overview and Portfolio Management
    • 6.6.2. Historical Deals Trend
    • 6.6.3. Biotechnology Exits and Initial Public Offerings in 2013
  • 6.7. Third Rock Ventures
    • 6.7.1. Overview and Portfolio Management
    • 6.7.2. Historical Deals Trend
    • 6.7.3. Biotechnology Exits and Initial Public Offerings in 2013
  • 6.8. Domain Associates
    • 6.8.1. Overview and Portfolio Management
    • 6.8.2. Historical Deals Trend
    • 6.8.3. Biotechnology Exits and Initial Public Offerings in 2013
  • 6.9. Kleiner Perkins Caufield & Byers
    • 6.9.1. Overview and Portfolio Management
    • 6.9.2. Historical Deals Trend
    • 6.9.3. Biotechnology Exits and Initial Public Offerings in 2013
  • 6.10. Clarus Ventures
    • 6.10.1. Overview and Portfolio Management
    • 6.10.2. Historical Deals Trend
    • 6.10.3. Biotechnology Exits and Initial Public Offerings in 2013
  • 6.11. Flagship Ventures
    • 6.11.1. Overview and Portfolio Management
    • 6.11.2. Historical Deals Trend
    • 6.11.3. Biotechnology Exits and Initial Public Offerings in 2013
  • 6.12. Additional Venture Capital Firms with Significant Biotechnology Investments
    • 6.12.1. Novo A/S
    • 6.12.2. InterWest Partners
    • 6.12.3. Essex Woodlands Health Ventures
    • 6.12.4. Alta Partners
    • 6.12.5. Third Security

7. Strategic Outlook

  • 7.1. New Financing Models Needed for Sustainable Growth of Emerging Biotechs
  • 7.2. Aggressive Growth Will Continue in the Asia-Pacific Region
  • 7.3. Small and Midsize Funds Will Enjoy Significant Deal Activity
  • 7.4. Initial Public Offering Activity Will Increase in 2014
  • 7.5. Increased Pressure on Venture Capital Firms

8. Appendix

  • 8.1. Bibliography
  • 8.2. Abbreviations
  • 8.3. Research Methodology
    • 8.3.1. Coverage
    • 8.3.2. Secondary Research
    • 8.3.3. Expert Panel Validation
  • 8.4. About the Authors
    • 8.4.1. Analyst
    • 8.4.2. Director of Healthcare Industry Dynamics
    • 8.4.3. Global Head of Healthcare
  • 8.5. About the Industry Dynamics Team
  • 8.6. About GlobalData
  • 8.7. Disclosure Information
  • 8.8. Disclaimer

List of Tables

  • Table 1: Significant Healthcare Private Equity Deals in 2013
  • Table 2: Top Healthcare Venture Capital Deals in 2013
  • Table 3: Breakdown of Venture Capital Investment Dollars in the US by Industry, 2008-2013 ($m)
  • Table 4: Significant Emerging Biotech Initial Public Offerings in 2013
  • Table 5: Intrexon: Pipeline of Partnered Products
  • Table 6: Ophthotech: Product Pipeline
  • Table 7: PTC Therapeutics: Product Pipeline
  • Table 8: Portola Pharmaceuticals: Product Pipeline
  • Table 9: Agios Pharmaceuticals: Product Pipeline
  • Table 10: Chimerix: Product Pipeline
  • Table 11: Bluebird Bio: Product Pipeline
  • Table 12: OncoMed Pharmaceuticals: Product Pipeline
  • Table 13: Acceleron Pharma: Product Pipeline
  • Table 14: Prosensa Therapeutics: Product Pipeline
  • Table 15: Epizyme: Product Pipeline
  • Table 16: Onconova: Product Pipeline
  • Table 17: Tetraphase Pharmaceuticals: Product Pipeline
  • Table 18: Esperion Therapeutics: Product Pipeline
  • Table 19: TPG Biotech: Current Investment Portfolio
  • Table 20: The Carlyle Group: Healthcare Portfolio
  • Table 21: The Blackstone Group: Healthcare/Pharma Private Equity Portfolio
  • Table 22: Kohlberg Kravis Roberts' Healthcare-Focused Global Private Equity Portfolio*
  • Table 23: Warburg Pincus: Healthcare Portfolio
  • Table 24: Advent International: Current Healthcare Investments
  • Table 25: Bain Capital Private Equity: Healthcare Portfolio
  • Table 26: CVC Capital's Current Healthcare-Related Investments
  • Table 27: Breakdown of Oaktree Capital Management's Assets by Class and Client Type*
  • Table 28: Hellman & Friedman: Current Healthcare Investments
  • Table 29: New Enterprise Associates: Current Biopharma Portfolio
  • Table 30: OrbiMed Advisors: Current Biopharmaceuticals Portfolio
  • Table 31: Canaan Partners' Ventures: Current Biopharmaceuticals Portfolio
  • Table 32: Versant Ventures: Current Biotechnology Portfolio
  • Table 33: New Leaf Venture Partners: Current Biopharmaceuticals Portfolio
  • Table 34: Third Rock Ventures: Current Biopharmaceuticals Portfolio
  • Table 35: Domain Associates: Current Biopharmaceuticals Portfolio
  • Table 36: Kleiner Perkins Caufield & Byers: Current Therapeutics Portfolio
  • Table 37: Clarus Ventures: Current Biotechnology Portfolio
  • Table 38: Flagship Ventures: Current Therapeutics Portfolio

List of Figures

  • Figure 1: Capital Commitments to Private Equity Firms, 2007-2013*
  • Figure 2: Venture Capital Fundraising, 2009-2013
  • Figure 3: Global Healthcare Private Equity Deal Trend (Volume and Value), 2006-2013
  • Figure 4: Global Healthcare Private Equity Deal Volume by Region, 2006-2013
  • Figure 5: Global Healthcare Private Equity Deal Value* by Region, 2006-2013
  • Figure 6: Global Healthcare Private Equity Deals by Therapy Area, 2013*
  • Figure 7: US Venture Capital Investment, 2009-2013
  • Figure 8: Composition of Venture Capital Investments in the US, 2013
  • Figure 9: Value of Venture Capital Investment in the US by Companies' Stage of Development, 2013
  • Figure 10: Volume of Venture Capital Investment Deals in the US by Companies' Stage of Development, 2013
  • Figure 11: Venture-Backed Initial Public Offerings and Merger and Acquisition Exits,* 2008-2013
  • Figure 12: Venture-Backed Merger and Acquisition Exits* in the US, 2008-2013
  • Figure 13: Venture-Backed Merger and Acquisition Exits* in the US, Q1 2013-Q4 2013
  • Figure 14: Venture Capital Investments in the US by Region, Q1 2013-Q3 2013
  • Figure 15: Completed Equity Offerings,* 2004-2013
  • Figure 16: Completed Venture-Backed Initial Public Offerings in the US, 2013
  • Figure 17: Current Assets to Total Assets Ratios of 15 Emerging Biotech Companies*
  • Figure 18: TPG Capital: Deals Trend, 2005-2012*
  • Figure 19: TPG Capital: Deals by Therapy Area, 2005-2011
  • Figure 20: Carlyle Group: Deals Trend, 2005-2013*
  • Figure 21: Carlyle Group: Deals by Therapy Area, 2005-2011
  • Figure 22: The Blackstone Group: Deals Trend, 2005-2013
  • Figure 23: The Blackstone Group: Deals by Therapy Area, 2005-2011
  • Figure 24: Kohlberg Kravis Roberts: Deals Trend, 2006-2013
  • Figure 25: Kohlberg Kravis Roberts: Deals by Therapy Area, 2005-2011
  • Figure 26: Warburg Pincus: Deals Trend, 2005-2012
  • Figure 27: Warburg Pincus: Deals by Therapy Area, 2005-2011
  • Figure 28: Goldman Sachs Capital Partners: Deals Trend, 2005-2011*
  • Figure 29: Goldman Sachs Capital Partners: Deals by Therapy Area, 2005-2011
  • Figure 30: Advent International: Deals Trend, 2005-2013
  • Figure 31: Advent International: Deals by Therapy Area, 2005-2011
  • Figure 32: Bain Capital: Deals Trend, 2005-2013*
  • Figure 33: CVC Capital Partners: Deals Trend, 2005-2011*
  • Figure 34: Oaktree Capital Management: Deals Trend, 2005-2013*
  • Figure 35: Hellman & Friedman: Deals Trend, 2007-2011
  • Figure 36: New Enterprise Associates: Deals Trend, 2005-2013
  • Figure 37: New Enterprise Associates: Deals by Therapy Area, 2005-2011
  • Figure 38: OrbiMed Advisors: Deals Trend, 2005-2013
  • Figure 39: OrbiMed Advisors: Deals by Therapy Area, 2005-2011
  • Figure 40: Canaan Partners: Deals Trend, 2005-2013
  • Figure 41: Canaan Partners: Deals by Therapy Area, 2005-2011
  • Figure 42: Versant Ventures: Deals Trend, 2005-2013
  • Figure 43: Versant Ventures: Deals by Therapy Area, 2005-2011
  • Figure 44: New Leaf Venture Partners: Deals Trend, 2005-2013
  • Figure 45: New Leaf Venture Partners: Deals by Therapy Area, 2005-2011
  • Figure 46: Third Rock Ventures: Deals Trend, 2005-2013
  • Figure 47: Third Rock Ventures: Deals by Therapy Area, 2005-2011
  • Figure 48: Domain Associates: Deals Trend, 2005-2013
  • Figure 49: Domain Associates: Deals by Therapy Area, 2005-2011
  • Figure 50: Kleiner Perkins Caufield & Byers: Deals Trend, 2005-2013
  • Figure 51: Kleiner Perkins Caufield & Byers: Deals by Therapy Area, 2005-2011
  • Figure 52: Clarus Ventures: Deals Trend, 2005-2013
  • Figure 53: Clarus Ventures: Deals by Therapy Area, 2005-2011
  • Figure 54: Flagship Ventures: Deals Trend, 2005-2013
  • Figure 55: Flagship Ventures: Deals by Therapy Area, 2005-2011
  • Figure 56: Novo A/S: Deals Trend, 2005-2013
  • Figure 57: Novo A/S: Deals by Therapy Area, 2005-2011
  • Figure 58: InterWest Partners: Deals Trend, 2005-2013
  • Figure 59: InterWest Partners: Deals by Therapy Area, 2005-2011
  • Figure 60: Essex Woodlands Health Ventures: Deals Trend, 2005-2013
  • Figure 61: Essex Woodlands Health Ventures: Deals by Therapy Area, 2005-2011
  • Figure 62: Alta Partners: Deals Trend, 2005-2013
  • Figure 63: Alta Partners: Deals by Therapy Area, 2005-2011
  • Figure 64: Third Security: Deals Trend, 2005-2013
  • Figure 65: Typical Financing Pathway of an Emerging Biotech Company
Back to Top